Search results for " Eradication"

showing 10 items of 32 documents

Pepsinogen testing for evaluation of the success of Helicobacter pylori eradication at 4 weeks after completion of therapy.

2014

Background and objective: Pepsinogen levels in plasma are increased by inflammation in the gastric mucosa, including inflammation resulting from Helicobacter pylori infection. A decrease in pepsinogen II level has been suggested as a reliable marker to confirm the successful eradication of infection. The aim of our study was to evaluate the potential role of pepsinogens I and II, gastrin-17 and H. pylori antibodies in confirming successful eradication. Material and methods: Altogether 42 patients (25 women, 17 men), mean age 45 years (range 23–74), were enrolled. Pepsinogens I and II, gastrin-17 and H. pylori IgG antibodies were measured in plasma samples using an ELISA test (Biohit, Oyj., …

AdultMalemedicine.medical_specialtyHelicobacter pylori infectionEfficacyGastrin-17macromolecular substancesPepsinogenGastroenterologydigestive systemHelicobacter InfectionsYoung AdultAtrophyPepsinInternal medicinePepsinogen AGastrinsmedicineGastric mucosaPepsinogen CHumansEradicationAgedMedicine(all)lcsh:R5-920biologyPlasma samplesHelicobacter pyloribusiness.industryHelicobacter pyloriMiddle Agedbiology.organism_classificationmedicine.diseaseAntibodies Bacterialdigestive system diseasesmedicine.anatomical_structureTreatment OutcomeGastric MucosaAutomotive Engineeringbiology.proteinPepsinogen IIPepsinogen; Gastrin-17; Eradication; <em>Helicobacter pylori</em>; EfficacyFemaleAntibodybusinesslcsh:Medicine (General)<em>Helicobacter pylori</em>BiomarkersMedicina (Kaunas, Lithuania)
researchProduct

[Vaccination against papillomavirus : arguments and evidence of effectiveness].

2020

Vaccination against papillomavirus: arguments and evidence of effectiveness. Vaccination against human papillomavirus is a major advance in the prevention of cervical cancer. Evidence of its effectiveness has accumulated over the past thirty years since basic research has demonstrated the ability of viral pseudoparticles to induce immune responses in animals. Large human clinical trials followed to demonstrate the safety and efficacy of vaccination against targeted HPV infections and their associated lesions. After its approval and marketing the vaccine efficacy was measured at the level of entire populations, confirming its effectiveness and medical interest. Today, models predict a possib…

MESH: HumansPapillomavirus InfectionsVaccinationUterine Cervical Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerMESH: Papillomavirus VaccinesMESH: VaccinationMESH: Papillomavirus InfectionsMESH: Uterine Cervical Neoplasms[SDV.CAN] Life Sciences [q-bio]/CancerHumansFemalePapillomavirus VaccinesDisease EradicationMESH: FemaleLa Revue du praticien
researchProduct

Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements

2021

The World Health Organization (WHO) targets for eliminating HCV by 2030 may be overambitious for many high-income countries. Recent analyses (ie, data from 2017 to 2019) show that only 11 countries are on track for meeting WHO’s elimination targets. For a country to be truly on track, it is important that the majority of infected individuals be identified and treated. There is still a need for country and population-specific evaluations within the different HCV screening and treatment strategies available, in order to assess their cost-effectiveness and sustainability and support an evidence-based policy for HCV elimination. Any health policy model is affected by the diversity and quality o…

media_common.quotation_subjectWorld Health Organizationdisease burden03 medical and health sciences0302 clinical medicineOrder (exchange)PandemicHumansQuality (business)Disease EradicationSet (psychology)Disease burdenHealth policymedia_commonPublic economicsHepatologyHCV screeningHealth PolicymicroeliminationCOVID-19Hepatitis CWHO targetHCV elimination030220 oncology & carcinogenesisSustainability030211 gastroenterology & hepatologyBusinessHumanDiversity (politics)Liver International
researchProduct

Is global elimination of HCV realistic?

2017

The elimination of hepatitis C virus (HCV) has been made possible through the availability of new antiviral drugs which may now be administered to all patients with HCV infection, even those with decompensated cirrhosis. The goal of the World Health Organization (WHO) is to reduce the incidence of chronic hepatitis infection from the current 6-10 million to 0.9 million cases of chronic infections by 2030, and annual deaths from 1.4 million to fewer than 0.5 million. Achieving these targets will require full implementation of epidemiological knowledge of HCV infection, screening and testing practices and strategies to link HCV patients to care. This review will focus on the current state of …

medicine.medical_specialtySustained Virologic ResponseHepatitis C virusCost-Benefit Analysismedicine.disease_causeGlobal HealthWorld Health OrganizationAntiviral AgentsWorld health03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicineEpidemiologymedicineHumansMass Screening030212 general & internal medicineDisease EradicationIntensive care medicineSubstance Abuse Intravenouslinkage to caredirect antiviral agentHepatologybusiness.industryscreeningIncidence (epidemiology)Hcv clearancevirus diseasesHepatologyPatient Acceptance of Health CareHepatitis Cdigestive system diseases030211 gastroenterology & hepatologybusinessPatient awarenessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Dracunculiasis: water-borne anthroponosis vs. food-borne zoonosis.

2019

Abstract Dracunculiasis is the first parasitic disease set for eradication. However, recent events related to the Dracunculus medinensis epidemiology in certain African countries are apparently posing new challenges to its eradication. Two novel facts have emerged: the existence of animal reservoirs (mainly dogs but also cats and baboons), and possibly a new food-borne route of transmission by the ingestion of paratenic (frogs) or transport (fish) hosts. Therefore, instead of being exclusively a water-borne anthroponosis, dracunculiasis would also be a food-borne zoonosis. The existence of a large number of infected dogs, mainly in Chad, and the low number of infected humans, have given ris…

Chad030231 tropical medicineZoologyBiologyCopepodaFoodborne Diseases03 medical and health sciences0302 clinical medicineDogsParatenicZoonosesmedicineAnimalsHumans030212 general & internal medicineDisease EradicationDisease ReservoirsDracunculiasisTransmission (medicine)ZoonosisDracunculiasisWaterGeneral Medicinemedicine.diseaseParasitic diseaseFood borneAfricaCatsFish <Actinopterygii>Animal Science and ZoologyParasitologyDracunculus medinensisJournal of helminthology
researchProduct

Current and future HCV therapy: do we still need other anti-HCV drugs?

2014

Eradication of hepatitis C virus (HCV) infection, at least in compensated patients, can help improve the outcomes of liver disease such as cirrhosis, hepatocellular carcinoma (HCC) and liver transplantation, as well as perhaps extra-hepatic complications such as diabetes and cardiovascular risk. In the past few years, the landscape of antiviral therapy has evolved at a breathtaking pace from pegylated interferon (PEG-IFN) plus ribavirin (RBV) (PEG-IFN/RBV) to IFN-based strategies combining direct acting antivirals (DDAs) with PEG-IFN/RBV and finally IFN-free combinations of DAAs. In particular with these most recent developments, treatment regimens have become shorter, safer and even more e…

medicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationChronic hepatitis Cmedicine.disease_causeAntiviral AgentsLiver diseasechemistry.chemical_compoundPegylated interferonmedicineHumansDisease EradicationIntensive care medicineAntiviral AgentHepaciviruHepatologybusiness.industryMedicine (all)Ribavirinmedicine.diseaseHepatitis CClinical researchchemistryHepatocellular carcinomaImmunologyDrug Therapy CombinationDirect antiviral agentTherapybusinessHumanmedicine.drugLiver International
researchProduct

Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe

2018

Abstract: Hepatitis C virus (HCV) infection is a major public health problem in the European Union (EU). An estimated 5.6 million Europeans are chronically infected with a wide range of variation in prevalence across European Union countries. Although HCV continues to spread as a largely silent pandemic, its elimination is made possible through the availability of the new antiviral drugs and the implementation of prevention practices. On 17 February 2016, the Hepatitis B & C Public Policy Association held the first EU HCV Policy Summit in Brussels. This summit was an historic event as it was the first high-level conference focusing on the elimination of HCV at the European Union level. The …

medicine.medical_specialtyCivil societyEconomic growthMedizinPublic policyHepacivirusAntiviral AgentsPatient advocacy03 medical and health sciences0302 clinical medicineVirologyPolitical sciencePandemicPrevalencemedicineHumansmedia_common.cataloged_instanceEuropean Union030212 general & internal medicineDisease EradicationEuropean unionmedia_commongeographySummitgeography.geographical_feature_categoryHepatologyPublic healthmedicine.diseaseHepatitis CEuropeInfectious DiseasesHCVEpidemiological Monitoring030211 gastroenterology & hepatologyHuman medicineViral hepatitisJournal of Viral Hepatitis
researchProduct

WHO delays guinea-worm disease eradication to 2020: are dogs the sole culprits?

2017

0301 basic medicinemedicine.medical_specialtyDisease reservoirDisease Eradicationbusiness.industry030231 tropical medicineDracunculiasis030108 mycology & parasitologyWorld Health Organization03 medical and health sciences0302 clinical medicineInfectious DiseasesDogsInternal medicineAfricamedicineAnimalsDog DiseasesDisease EradicationbusinessDisease ReservoirsThe Lancet. Infectious diseases
researchProduct

Global prevalence and genotype distribution of hepatitis C virus infection in 2015:a modelling study

2017

WOS: 000426979400014

Viremia/epidemiologyPopulation ageingmedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDDelphi TechniqueGenotypeVoxilaprevirGenotype Global Health Hepatitis C Eradication Modelling studyMedicina Clínicaddc:616.07Global HealthBioinformatics03 medical and health sciences0302 clinical medicineCost of IllnessEpidemiologyJournal ArticlemedicineGlobal healthPrevalenceHumansViremia030212 general & internal medicineDisease EradicationDisease burdenddc:616HepatologyHepatitis C Chronic/epidemiologybusiness.industryGastroenterologyHepatitis CGlecaprevirHepatitis C Chronicmedicine.diseaseViremia/epidemiology/geneticsPibrentasvirGlobal Health/statistics & numerical dataHCVHEPATITIS C030211 gastroenterology & hepatologyMedicina Critica y de EmergenciaHuman medicinebusinessChronic/epidemiology/genetics/prevention & controlDemography
researchProduct

LC-QTOF-MS and 1H NMR Metabolomics Verifies Potential Use of Greater Omentum for Klebsiella pneumoniae Biofilm Eradication in Rats

2020

Bacterial wound infections are a common problem associated with surgical interventions. In particular, biofilm-forming bacteria are hard to eradicate, and alternative methods of treatment based on covering wounds with vascularized flaps of tissue are being developed. The greater omentum is a complex organ covering the intestines in the abdomen, which support wound recovery following surgical procedures and exhibit natural antimicrobial activity that could improve biofilm eradication. We investigated changes in rats&rsquo

Microbiology (medical)Klebsiella pneumoniae<i>Klebsiella pneumoniae</i>implantslcsh:Medicinemacromolecular substancesArticleMicrobiologysurgery03 medical and health sciencesmicrobial biofilm eradication0302 clinical medicinePeritoneummedicineMetabolomeImmunology and Allergy030212 general & internal medicineMolecular BiologyGeneral Immunology and Microbiologybiologyintegumentary systembusiness.industrylcsh:RBiofilmGreater omentumbiology.organism_classificationAntimicrobialmetabolomicsbody regionsKlebsiella pneumoniaeInfectious Diseasesmedicine.anatomical_structureImplantbusinessWound healing030217 neurology & neurosurgeryPathogens
researchProduct